Document text
Principal Investigator: KWANHA YU
Organization: BAYLOR COLLEGE OF MEDICINE
Fiscal Year: 2024
Award: $152,274
Funding agency: National Cancer Institute
Glioma is the most common and deadly disease affecting the CNS. Current projections suggest 22,000 new
cases annually, of which 13,000 will be Glioblastoma Multiforme, which is universally fatal. Despite over 60
years of research, there have been no significant improvements to patient outcome. More recently, high
throughput molecular sequencing technology has open the field of genomics and big data, in the hopes of
providing novel insight to the disease and potential therapeutic inroads. However, these efforts have largely
served to refine diagnosis rather than improve patient prognosis. In an effort to translate the wealth of patient
genomics information beyond identifying novel informatics trends, our program seeks to biologically
functionalize genomics information. More specifically, we have developed tools and approaches that overcome
the pragmatic hurdles of traditional methods. We have taken our previously developed in utero electroporation-
glioma model and added barcode targeting next generation sequencing, resulting in a fully in vivo, non-viral
screening system to test at least 50 different genetic factors. In advancing forward, we seek to: 1) further
pursue our previous findings to understand the molecular mechanisms driving the phenomenon we’ve
observed, 2) advance and upgrade our methods to meet the needs of other systems, and 3) apply our
approach to investigate glioma-associated epilepsy, an associated co-morbidity. Our larger initiative in
functional genomics will: 1) provide new tools and methods for screening and testing genetic anomalies found
in glioma, 2) provide molecular insight into the mechanism that differentially promote variant specific
gliomagenesis within an allelic series, 3) begin to demonstrate the unique biology of familial glioma, and 4)
further investigate the mechanisms underlying glioma driven hyperexcitably thereby addressing a much under
investigated quality of life concern. Ultimately, our programs exists to gain greater insight into the molecular
mechanisms that drive gliomagenesis and associated co-morbidities. This will provide understanding towards
novel therapeutic vulnerabilities.
Terms: <Address><Affect><Alleles><Allelomorphs><Automobile Driving><Bar Codes><Big Data><BigData><Biologic Models><Biological Models><Biology><CNS Nervous System><Cancers><Central Nervous System><Diagnosis><Disease><Disorder><Electroporation><Epilepsy><Epileptic Seizures><Epileptics><Genetic><Genomics><Glial Cell Tumors><Glial Neoplasm><Glial Tumor><Glioblastoma><Glioma><Gliomagenesis><Grade IV Astrocytic Neoplasm><Grade IV Astrocytic Tumor><Grade IV Astrocytoma><Informatics><Malignant Neoplasms><Malignant Tumor><Methods><Model System><Modeling><Molecular><NGS Method><NGS system><Neuraxis><Neuroglial Neoplasm><Neuroglial Tumor><Pathway interactions><Patient outcome><Patient-Centered Outcomes><Patient-Focused Outcomes><Patients><QOL><Quality of life><Research><Seizure Disorder><Series><System><Technology><Testing><Therapeutic><Translating><Variant><Variation><barcode><co-morbid><co-morbidity><comorbidity><driving><electroporative delivery><epilepsia><epileptogenic><functional genomics><gene electrotransfer><gene testing><gene-based testing><genetic testing><genomic data><genomic data-set><genomic dataset><glial-derived tumor><glioblastoma multiforme><glioma genesis><improved><in utero><in vivo><insight><malignancy><neoplasm/cancer><neuroglia neoplasm><neuroglia tumor><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutics><new therapy><next gen sequencing><next generation sequencing><next generation therapeutics><nextgen sequencing><novel><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel therapeutics><novel therapy><pathway><patient oriented outcomes><patient prognosis><personalization of treatment><personalized medicine><personalized therapy><personalized treatment><programs><screening><screenings><spongioblastoma multiforme><tool><trend>